A Phase 1 Study to Evaluate Relative Bioavailability and Food Effect of an ALG-097558 Tablet Formulation and the Drug-Drug Interaction Potential of ALG-097558 and Its Metabolite ALG-097730 in Healthy Volunteers
Latest Information Update: 28 May 2025
At a glance
- Drugs ALG-097558 (Primary) ; Dabigatran etexilate; Itraconazole
- Indications COVID 2019 infections
- Focus Pharmacokinetics
Most Recent Events
- 20 May 2025 Status changed from not yet recruiting to recruiting.
- 14 May 2025 Planned initiation date changed from 25 Apr 2025 to 16 May 2025.
- 06 May 2025 According to Aligos therapeutics media release, this NIAID sponsored drug-drug interaction and relative bioavailability study of ALG-097558 in healthy volunteers is expected to start dosing in Q2 2025.